Literature DB >> 23055382

[Humoral immune anti-Plasmodium falciparum AMA1 and MSP1 response in two ethnic groups living in sympatry in Mali].

A Dolo1, M Coulibaly, B Maïga, M Daou, C Arama, M Troye-Blomberg, O Doumbo.   

Abstract

Fulani of Mali are known for their lower susceptibility to Plasmodium falciparum malaria than their neighbours, the Dogon, despite similar transmission conditions. However, the mechanisms underlying these differences are poorly understood, particularly those concerning antigenspecific immune responses. The Apical Membrane Antigen 1 (AMA1) and the Merozoite Surface Antigen 1 (MSP1) are two malaria vaccine candidates, which play a pivotal role during the invasion of parasites into erythrocytes, and in the case of AMA1, of hepatocytes. Therefore, we analyzed the level of anti-AMA1 and anti-MSP1 antibodies (FVO and 3D7 alleles), by using ELISA (Enzyme Linked Immuno Sorbent Assay) to investigate whether there are differences between the two ethnic groups. Our results show that the splenic rate, the level of anti-AMA1 and anti-MSP1 were significantly higher in Fulani compared to Dogon; while the parasite rate was lower in Fulani group compared to Dogon. Our results suggest that the lower susceptibility of Fulani to malaria could be due to the higher specific humoral responses against AMA1 and MSP 1 in Fulani's ethnic group compared to Dogon.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23055382     DOI: 10.1007/s13149-012-0262-9

Source DB:  PubMed          Journal:  Bull Soc Pathol Exot        ISSN: 0037-9085


  2 in total

Review 1.  Do advanced glycation end-products play a role in malaria susceptibility?

Authors:  Karim Traoré; Charles Arama; Maurice Médebielle; Ogobara Doumbo; Stéphane Picot
Journal:  Parasite       Date:  2016-03-24       Impact factor: 3.000

2.  Interaction between environment, nutrient-derived metabolites and immunity: A possible role in malaria susceptibility/resistance in Fulani and Dogon of Mali.

Authors:  Karim Traore; Mahamadou A Thera; Anne-Lise Bienvenu; Charles Arama; Guillaume Bonnot; Adeline Lavoignat; Ogobara K Doumbo; Stephane Picot
Journal:  PLoS One       Date:  2017-12-20       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.